Medline (NASDAQ:MDLN) Price Target Raised to $60.00 at Citigroup

Medline (NASDAQ:MDLN) had its price target upped by Citigroup from $48.00 to $60.00 in a research note released on Thursday,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other equities analysts have also weighed in on MDLN. Zacks Research raised Medline to a “hold” rating in a research note on Tuesday, January 13th. BTIG Research restated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of Medline in a report on Wednesday, January 21st. Bank of America started coverage on shares of Medline in a research report on Monday, January 12th. They set a “buy” rating and a $50.00 price target on the stock. BMO Capital Markets increased their price objective on shares of Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Tigress Financial began coverage on shares of Medline in a research note on Thursday, February 5th. They issued a “buy” rating and a $55.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Medline currently has an average rating of “Moderate Buy” and a consensus price target of $50.15.

Medline Price Performance

Shares of NASDAQ MDLN opened at $48.89 on Thursday. The company’s fifty day moving average is $44.40. Medline has a 52-week low of $34.89 and a 52-week high of $50.88.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The company had revenue of $7.79 billion during the quarter, compared to analysts’ expectations of $7.52 billion. The business’s revenue was up 14.8% on a year-over-year basis.

Insider Buying and Selling at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles N. Mills purchased 2,579,310 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. This represents a -1,870.00% increase in their position. The disclosure for this purchase is available in the SEC filing.

Institutional Trading of Medline

Several large investors have recently modified their holdings of MDLN. Chung Wu Investment Group LLC purchased a new stake in shares of Medline during the fourth quarter worth about $155,000. North Star Investment Management Corp. acquired a new stake in Medline during the 4th quarter valued at approximately $36,000. NBC Securities Inc. purchased a new stake in Medline during the 4th quarter worth approximately $28,000. Pictet Asset Management Holding SA purchased a new stake in Medline during the 4th quarter worth approximately $48,996,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in shares of Medline in the 4th quarter valued at approximately $2,768,000.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple major firms raised price targets and ratings following Q4 — Citigroup to $60 (buy), UBS to $57 (buy), BMO to $54 (outperform) and RBC to $53 (outperform). These upgrades signal renewed analyst conviction and likely support near‑term buying interest.
• Positive Sentiment: Q4 revenue beat and strong growth: Medline reported Q4 net sales of ~$7.8B (up 14.8% YoY) and full‑year net sales of $28.4B, driven by new customer signings — a validation of the company’s scale and demand. Medline Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management issued 2026 guidance calling for Organic Sales growth of 8–9% and Adjusted EBITDA of $3.5–$3.6B, which supports a positive growth narrative despite near‑term margin headwinds. Medline Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst coverage roundup and notes on upgraded forecasts after Q4 provide context for the rating moves but aggregate guidance and assumptions vary by shop. Medline Analysts Boost Their Forecasts Following Q4 Results
• Neutral Sentiment: Earnings call and transcript are available for detailed read‑throughs of management’s commentary on customer wins, supply‑chain actions and cost drivers. Medline Inc. (MDLN) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Valuation pieces are appearing as shares move; some note momentum but also emphasize the need to weigh price against near‑term margin pressure. Assessing Medline (MDLN) Valuation After Recent Share Price Momentum
• Negative Sentiment: Earnings per share missed consensus — reported ($0.01) vs. street ~$0.24 — driven by higher cost of goods sold, tariffs and IPO-related expenses; this explains some investor caution on near‑term profitability. Medline Q4 Press Release / Financial Tables
• Negative Sentiment: Net income and adjusted margins were down (Q4 net income -37.7% YoY; Adjusted EBITDA roughly flat) and management cited tariff, inventory and investment costs — risks that could compress margins if cost pressures persist. Quiver Quant Summary

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.